GSK forms Joint Venture to Tap China’s Vaccine Market
By Taskin Ahmed
PharmaDeals Review: Vol 2009 Issue 10 (Table of Contents)
Published: 12 Oct-2009
DOI: 10.3833/pdr.v2009i10.1257 ISSN: 1756-7874
Section: Joint Venture
Fulltext:
Abstract
GlaxoSmithKline (GSK) and Jiangsu Walvax Biotech Company (Walvax) sign an agreement to form a JV to produce the measles, mumps and rubella (MMR) and other vaccines in China in a cost and equity sharing deal valued at GB£41...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login on the top right purple box.
Copyright: PharmaVentures Ltd
RSS